Budesonide Nasal Irrigation Versus Fluticasone Propionate Nasal Spray in Treating Allergic Rhinitis Patients
NCT ID: NCT06858423
Last Updated: 2025-03-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
360 participants
INTERVENTIONAL
2023-08-15
2024-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Budesonide Irrigation in Allergic Rhinitis
NCT06785662
Demonstration of Equivalence and Early Onset of a Novel Anti-allergic Nasal Spray Compared to Marketed Nasal Spray
NCT03755557
Rhinocort Aqua Versus Placebo and Fluticasone Propionate
NCT00641680
Nasal Budesonide Efficacy on Nasal FeNO in Children With Allergic Rhinitis
NCT02409563
Compare CE-Budesonide Nasal Solution & Rhinocort Aqua in an EEC Study of AR
NCT00938613
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A (Saline Group)
120 patients used 0.9% saline for nasal irrigation.
0.9% saline for nasal irrigation.
120 patients used 0.9% saline for nasal irrigation.
Group B (Fluticasone Propionate Nasal Spray)
120 patients received fluticasone propionate nasal spray.
Fluticasone propionate nasal spray.
120 patients received fluticasone propionate nasal spray.
Group C (Budesonide Nasal Irrigation)
120 patients received budesonide buffered with 0.9% isotonic saline.
Budesonide buffered with 0.9% isotonic saline.
120 patients received budesonide buffered with 0.9% isotonic saline.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Budesonide buffered with 0.9% isotonic saline.
120 patients received budesonide buffered with 0.9% isotonic saline.
Fluticasone propionate nasal spray.
120 patients received fluticasone propionate nasal spray.
0.9% saline for nasal irrigation.
120 patients used 0.9% saline for nasal irrigation.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with allergic rhinitis evidence by past skin prick testing. Patients were given a skin prick test with a panel of dog, cat, Dermatophagoides farinae, D pteronyssinus, Alternaria, Penicillium, Hormodendron, Aspergillus, grass pollen mix, tree pollen mix, and ragweed allergen extracts (100,000 Allergen Unit/mL). Histamine, 10 mg/mL, was used as a positive control, and the diluent was used as the negative control. A positive reaction was defined as a wheal diameter at least 3 mm greater than the diluent control and/or at least a 50-mm flare (ie, erythema measured as the sum of the greatest diameter and the perpendicular diameter through the midpoint of the greatest diameter)
Exclusion Criteria
* Patients with a history of nasal surgery.
* Patients who received systemic or topical corticosteroids, herbal drugs, beta blocking agent within the previous month of enrolment.
* Patients with asthma and COPD, nasal bleeding, obstructing nasal polyps, paranasal sinus.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Benha University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eslam Farid Abu Shady ,MD
Lecturer and consultant of otolaryngology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Benha University Hospitals - Otolaryngology department
Banhā, Qalyobia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MS-8-8-2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.